Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
FY2025 · 10-K disclosure
Current price $441.19
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 23, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 2, 26 | Kaye Mark | officer: EVP & CFO | A-Award | 2,627 | — |
| TD Cowen |
| maintain |
| Buy |
| Buy |
| Oct 22, 26 | UBS | maintain | Buy | Buy |
| Oct 22, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 22, 26 | Barclays | maintain | Overweight | Overweight |
| Oct 22, 26 | Baird | maintain | Neutral | Neutral |
| Oct 22, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Oct 22, 26 | Guggenheim | maintain | Buy | Buy |
| Oct 12, 26 | Guggenheim | maintain | Buy | Buy |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Oct 2, 26 |
| Kaye Mark |
| officer: EVP & CFO |
| F-InKind |
| 4,161 @ $386.43 |
| $1.61M |
| Sep 2, 26 | Wessling Erin M | officer: EVP & Chief Legal Officer | F-InKind | 94 @ $405.84 | $38.15K |
| Sep 3, 26 | Wessling Erin M | officer: EVP & Chief Legal Officer | F-InKind | 255 @ $414.78 | $105.8K |
| Sep 2, 26 | Craig Ryan R | officer: EVP & Chief HR Officer | F-InKind | 144 @ $405.84 | $58.44K |
| Jul 17, 26 | Peru Ramiro G | director | P-Purchase | 1,000 @ $366.05 | $366.1K |
| Jul 17, 26 | Boudreaux Gail | director, officer: President and CEO | P-Purchase | 2,045 @ $368.25 | $753.1K |
| Jul 17, 26 | Boudreaux Gail | director, officer: President and CEO | P-Purchase | 680 @ $366.41 | $249.2K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ELV | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 18.8x | 17.2x · sector 20.7x | In line |
| Forward P/E (FY26E) | 15.4x | EPS est. 28.64 | Discount |
| Price / Book | 2.1x | 2.6x | Discount |
| Price / Sales | 0.5x | 0.6x | Discount |
| EV / EBITDA | 13.1x | 12.1x | In line |
| Return on equity | 11.6% | — | Healthy |
| Gross margin | 36.6% | 26.5% | Above hist. |
| Debt / Equity | 0.69 | 0.73 | Moderate |
| Piotroski / Altman Z | 7/9 | Z 3.08 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?
Elevance Health raised its 2026 adjusted EPS guidance to at least $29, but the sustainability of its earnings recovery remains uncertain. Third-quarter adjusted EPS rose 15.9%, while nine-month operating gain declined 25.7%, highlighting the gap between improving earnings and underlying profitability. Health Benefits margins remain under pressure, particularly in Medicaid, despite improving medical cost trends and stronger quarterly results.
Elevance raised its 2026 earnings baseline to at least $26.75 per share. Carelon's cancer program reduced avoidable inpatient admissions by 15%.
Intuitive Surgical (ISRG) and Elevance Health (ELV) delivered impressive Q3 earnings beats, making both healthcare stocks worth considering as their growth outlooks improve.
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Elevance Health, Inc. (ELV) Q3 2026 Earnings Call Transcript
Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
Elevance Health NYSE: ELV raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company's expectations as Medicaid, Medicare Advantage and Individual ACA businesses all performed better than anticipated.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 21, 2026 | 4.71 | 6.99 | Beat 48.4% | $50.44B |
| Jul 15, 2026 | 6.21 | 7.45 | Beat 20.0% | $49.83B |
| Apr 22, 2026 | 10.82 | 12.58 | Beat 16.3% | $49.49B |
| Jan 28, 2026 | 3.10 | 3.33 | Beat 7.4% | $49.31B |
| Oct 21, 2025 | 4.93 | 6.03 | Beat 22.3% | $50.09B |
| Jul 17, 2025 | 8.91 | 8.84 | Miss -0.8% | $49.42B |
1255 daily bars · split adjusted
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Oct 21, 2026 | 2026-10-21 14:14:36 | View |
| 8-K | Oct 21, 2026 | 2026-10-21 06:01:36 | View |
| 4 | Oct 6, 2026 | 2026-10-06 16:02:46 | View |
| 8-K | Sep 10, 2026 | 2026-09-10 06:00:47 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:06:17 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:05:26 | View |
| 4 | Jul 17, 2026 | 2026-07-17 15:04:55 | View |
| 4 | Jul 17, 2026 | 2026-07-17 13:50:44 | View |
| 10-Q | Jul 15, 2026 | 2026-07-15 11:27:18 | View |
| 8-K | Jul 15, 2026 | 2026-07-15 06:01:33 | View |
Proxy statement (DEF 14A) disclosures
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 67.44 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 83.75 | Oscillator | Sell |
| Williams %R (14) | -16.87 | Oscillator | Sell |
| MACD (12, 26, 9) | 10.44 (Hist 3.24) | Oscillator | Strong Buy |
| Average Directional Index (14) | 27.23 (+DI 26.4 / -DI 9.6) | Trend | Strong Buy |
| EMA 20 | 421.73 | MA | Strong Buy |
| SMA 20 | 414.00 | MA | Strong Buy |
| EMA 50 | 410.23 | MA | Strong Buy |
| SMA 50 | 408.07 | MA | Strong Buy |
| SMA 200 | 371.14 | MA | Strong Buy |